As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...
As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better in other diseases. Arda Therapeutics has raised a $43 ...
Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark in a Phase 2 mild cognitive impairment trial. The drug, an NMDA receptor ...
Johnson & Johnson’s drug-device combo has disappointed in a late-stage test in people with an advanced form of bladder cancer but it says it is still confident in the technology's overall blockbuster ...
Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation ...
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...
Scholar Rock announced its experimental add-on treatment for spinal muscular atrophy significantly improved motor function ...
AstraZeneca is strengthening its cardiovascular disease pipeline with a $100 million upfront deal for a lipid-targeting drug ...
Dedicated to the memory of Natalie Grover, who co-created the Women in Biopharma R&D special report while she was a reporter ...
The news that Pfizer has an activist isn’t a surprise. For the last few months at Endpoints News, we’ve been asking which ...
Many drug price proposals from candidates and Congress won't have much effect, analysis finds
Want to lower drug prices? Good luck. In a new report released Friday, the nonpartisan Congressional Budget Office (CBO) detailed how many of the campaign proposals mentioned by presidential nominees ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback